Avecia, Oligo manufacturing facility expansion
DPS provided detailed design services to assist Avecia in increasing its oligonucleotide API manufacturing capacity with a 20,000SF expansion.
About this project
This project provides cGMP oligonucleotide manufacturing capacity up to 1.8mol, more than doubling its total capacity up to 3.0mol, making it the largest oligonucleotide manufacturing site in the world.
The DPS team also designed the facility to accommodate the unit operations of synthesis, buffer preparation, small and large chromatography, cleavage/deprotect, UF/TFE, and freeze drying. The new room layouts achieved the operations of a larger scale synthesis and chromatography suites than the existing. The DPS team also designed an additional 7,400 sf of space to accommodate the unit operations of synthesis, buffer preparation, small and large chromatography process than the existing building.
Additionally, the design included equipment cleaning, equipment storage, flammable storage, cold storage, process utilities, USP water, and building mechanical systems. Although the expansion is considered a separate building, to conform to building code requirements of high hazard H-3 areas, the operations were integrated and coordinated with the existing Building 155’s operations.
Tell us about your project
and discover how DPS can help you today